AACR 2024 Invitation
Please make sure to check our poster in the AACR exhibition area, highlighting the following title:
- KY-HC mouse: A low-cost and fast nanoantibody discovery platform
- KY-CLC mouse: Universal Light Chain Bispecific Antibody Discovery Platform
- The bispecific antibody KA-3008 targets both EGFR and B7H3 simultaneously, enhancing internalization and minimizing targeting and extratumoral toxicity to the greatest extent possible
- The dual complementary antibody KA-3005 targeting MET is suitable for developing antibody drug conjugates (ADCs) for the treatment of cancer expressing MET
- The efficacy of the bispecific antibody KA-3006 against EGFR and MET is superior to that of amivolumab
- Bispecific antibody KA-3001 specifically enhances T cell activation in prostate tumors by targeting PSMA and CD28
- The LN18-MRTX1719R cell line is a useful cell model for discovering novel PRMT5 inhibitors.
- InnoPanel TM and InnoPedia TM: Engineering cell lines and xenograft resources for drug discovery
- Kyinno PBMC Humanized Mouse Platform: A groundbreaking service for biomedical research
- Keno Technology Antibody Production and Expression Platform
- MPSA-AB5000: High throughput membrane protein screening array for specific analysis of therapeutic biological products
- Ba/F3 AKT engineering cell line, a useful platform for new drug discovery
- Ba/F3-BCR-ABL engineered cell line panel, a useful platform for new drug discovery
- Cell line combinations with HIBIT labeled endogenous proteins can accelerate the discovery of PROTAC drugs
We look forward to communicating with you at AACR 2024 and sharing our insights on the innovative work of Kyino Biotechnology. Don’t miss this opportunity to build a network and discover exciting opportunities!